Phaseline

Companies › Shanghai EpimAb Biotherapeutics

Shanghai EpimAb Biotherapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bafisontamab (EMB-01)
Hepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
MET, EGFRPhase 2Metastatic Colorectal Cancer; Unresectable/Metastatic Colorectal CancerDec 2027
EMB-07
Bispecific antibody targeting CD3 and ROR1
CD3, ROR1Phase 1Combination TherapyJun 2028
EMB-15
Bi-specific antibody against ALPP/ALPG and CD3; T-cell engager
ALPP, ALPG, CD3Phase 1Locally Advanced or Metastatic Solid TumorsMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07314294Bafisontamab (EMB-01)Phase 2Metastatic Colorectal CancerOncologyDec 2027
NCT07649655Bafisontamab (EMB-01)Phase 1Unresectable/Metastatic Colorectal CancerOncologyMar 2028
NCT07432022EMB-07Phase 1Combination TherapyOncologyJun 2028
NCT07607054EMB-15Phase 1Locally Advanced or Metastatic Solid TumorsOncologyMay 2029

Targets

CD3 (2) MET (1) EGFR (1) ALPP (1) ALPG (1) ROR1 (1)

Companies with the same targets

AstraZeneca Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Shanghai Henlius Biotech Betta Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Pierre Fabre Medicament Allist Pharmaceuticals Dizal Pharmaceuticals

Companies built like this

iTeos Therapeutics SUNHO(China)BioPharmaceutical Takara Bio OBI Pharma ALX Oncology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.